NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-NS-18-074 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-RM-18-021 from the NIH Guide for Grants and Contracts. To solicit applications for pilot projects on IDG-eligible understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels) in order to study them beyond what the IDGs Centers can accomplish, and to validate and demonstrate the utility of IDG reagents, data, and approaches.
Funding Opportunity RFA-AR-19-013 from the NIH Guide for Grants and Contracts. The NIAMS Research Innovation for Scientific Knowledge (RISK) for Musculoskeletal Diseases (R61/R33) initiative focuses on innovative research within the NIAMS mission by encouraging applicants to pursue unusual observations, test imaginative hypotheses, investigate creative concepts, and build ground-breaking paradigms, all of which deviate significantly from the current prevailing theories or practice. This FOA is particularly designed to encourage the submission of projects that are considered too risky, premature, controversial, or unconventional for other NIH mechanisms. This FOA intends to support disease-focused translational studies. We invite research studies aimed at understanding the mechanisms of diseases or conditions relevant to the NIAMS mission, as well as studies aimed at developing or testing diagnostics, therapeutic agents, or preventive interventions up to, but not including, first in human studies. The RISK R61/R33 FOAs are not intended to support clinical trials.
Funding Opportunity PAR-18-865 from the NIH Guide for Grants and Contracts. The NIAMS Research Innovation for Scientific Knowledge (RISK) for Musculoskeletal Diseases initiative focuses on innovative research within the NIAMS mission by encouraging applicants to pursue unusual observations, test imaginative hypotheses, investigate creative concepts, and build ground-breaking paradigms, all of which deviate significantly from the current prevailing theories or practice. This FOA is particularly designed to encourage the submission of projects that are considered too risky, premature, controversial, or unconventional for other NIH mechanisms. This FOA intends to support disease-focused translational studies. We invite research studies aimed at understanding the mechanisms of diseases or conditions relevant to the NIAMS mission, as well as studies aimed at developing or testing diagnostics, therapeutic agents, or preventive interventions up to, but not including, first in human studies. The RISK R61/R33 FOAs are not intended to support clinical trials.
Notice NOT-OD-18-212 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-18-863 from the NIH Guide for Grants and Contracts. The purpose of this funding announcement (FOA) issued by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) of the National Institutes of Health (NIH) is to encourage research grant applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination.
Funding Opportunity PA-18-861 from the NIH Guide for Grants and Contracts. The purpose of this funding announcement (FOA) issued by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) of the National Institutes of Health (NIH) is to encourage research grant applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination.
Funding Opportunity PA-18-862 from the NIH Guide for Grants and Contracts. The purpose of this funding announcement (FOA) issued by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) of the National Institutes of Health (NIH) is to encourage research grant applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination.
Funding Opportunity RFA-HL-19-025 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to enhance the pool of highly trained investigators from diverse backgrounds underrepresented in research. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. This FOA invites applications from institutions with eligible faculty members to undertake special study and supervised research under a mentor who is an accomplished investigator in the research area proposed and has experience in developing independent investigators. This FOA is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion FOA (see RFA-HL-19-026).
Funding Opportunity RFA-HL-19-026 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to enhance the pool of of highly trained investigators from diverse backgrounds underrepresented in research. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. This FOA invites applications from Institutions with eligible faculty members to undertake special study and supervised research under a mentor who is an accomplished investigator in the research area proposed and has experience in developing independent investigators. This FOA is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (see RFA-HL-19-025).
Funding Opportunity PAR-18-860 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support short-term exploratory, developmental, and transdisciplinary research to understand the immunologic events that occur during blood feeding by hematophagous arthropods. The scientific objectives of this initiative are (1) to understand the immunological events in the vertebrate host, which occur during and after blood feeding by hematophagous arthropods, at the bite site (skin) and systemically; (2) to identify and characterize the immune modulatory properties of arthropod salivary components; and (3) to understand the immunological events in the hematophagous arthropods following a blood meal.
Funding Opportunity PAR-18-864 from the NIH Guide for Grants and Contracts. The National Eye Institute (NEI) supports investigator-initiated, complex, multi-center and other high resource risk epidemiologic studies under the cooperative agreement mechanism, UG1 activity code. Specifically, the purpose of this Funding Opportunity Announcement (FOA) is to support new and innovative ocular epidemiology research.
Notice NOT-DA-18-028 from the NIH Guide for Grants and Contracts
Notice NOT-DK-18-019 from the NIH Guide for Grants and Contracts
Notice NOT-OD-18-209 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-18-859 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support research activities that will advance NIAIDs mission to develop a universal influenza vaccine providing durable protection against multiple influenza strains, including efforts to: 1) improve understanding of transmission, natural history and pathogenesis of influenza virus infection; 2) characterize influenza immunity and correlates of immune protection; and 3) support rational design of universal influenza vaccines. This FOA uses the R01 grant mechanism, while the companion FOA, PA-XX-xxx , uses the R21 mechanism. Applicants with preliminary data and/or planning longer-term studies may wish to apply using the R01 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism. .
Funding Opportunity PA-18-858 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support research activities that will advance NIAIDs mission to develop a universal influenza vaccine providing durable protection against multiple influenza strains, including efforts to: 1) improve understanding of transmission, natural history and pathogenesis of influenza virus infection; 2) characterize influenza immunity and correlates of immune protection; and 3) support rational design of universal influenza vaccines. This FOA uses the R21 grant mechanism, while the companion FOA, PA-XX-xxx , uses the R01 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism. Applicants with preliminary data and/or planning longer-term studies may wish to apply using the R01 mechanism.
Notice NOT-OH-18-010 from the NIH Guide for Grants and Contracts
Notice NOT-HG-18-010 from the NIH Guide for Grants and Contracts
Notice NOT-OD-18-211 from the NIH Guide for Grants and Contracts